- 1Medical Office, A.E.S., Chorley PR7 1NY, Lancashire, United Kingdom. email@example.com.
- 2Chief Medical Office, Accelerated Enrollment Solutions, Horsham, PA 19044, United States.
Background: There is an acute need to raise awareness of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) among primary care physicians, endocrinologists and diabetologists to improve patient identification and address the current difficulties in NASH clinical trial enrollment. We examined the extent of knowledge and practice regarding NASH diagnosis and management guidelines. A randomized online convenience survey of 12869 physicians drawn from a national physician database of primary care physicians (PCPs), and gastroenterology and endocrinology specialists were queried via online survey. Our results, based on a cohort of 185 respondents, showed gaps in knowledge and practice between these three groups of practitioners, with primary care providers having the lowest adherence to published guidelines for diagnosis of NASH. Without clear knowledge and patient identification at the point of presentation - which is often in primary care or with specialties other than hepatology-many patients with NAFLD and NASH will remain undiagnosed and untreated, and clinical studies will continue to struggle with patient recruitment, hindering clinical development and optimal patient care.
Aim: To determine knowledge base concerning NASH diagnosis amongst gastroenterologists, endocrinologists and primary care physicians to improve referrals into clinical trials.
Methods: A randomized online convenience survey of 12869 physicians drawn from a national physician database of PCPs, and gastroenterology and endocrinology specialists was conducted yielding a sample of 185 respondents.
Results: The survey revealed that many physicians are either unaware of testing options other than biopsy, or do not use them in practice. Only 46% of endocrinologists and 42% of primary care physicians indicated they would refer a patient for specialist workup if they suspected NASH. Risk (25%) and inconvenience to patients (18%) are given as reasons for not referring those with suspected NASH for biopsy. For standard diagnostic algorithms such as Fibrosis-4 score, 18% of PCPs, 30% of endocrinologists and 65% gastroenterologists reported using these tests in clinical practice.
Conclusion: Substantial gaps in knowledge of the differences between NAFLD and NASH exist between these physician groups, with knowledge being particularly low among primary care doctors and endocrinologists. The use of a simple non-invasive screening algorithm may help to identify the right patients for clinical trials, which in turn will be vital to the development of effective and well-tolerated treatments for this increasingly ubiquitous condition.